SI20644B - Ekspresijski sistem za faktor viii - Google Patents
Ekspresijski sistem za faktor viii Download PDFInfo
- Publication number
- SI20644B SI20644B SI9920097A SI9920097A SI20644B SI 20644 B SI20644 B SI 20644B SI 9920097 A SI9920097 A SI 9920097A SI 9920097 A SI9920097 A SI 9920097A SI 20644 B SI20644 B SI 20644B
- Authority
- SI
- Slovenia
- Prior art keywords
- protein
- factor viii
- cells
- crl
- expressed
- Prior art date
Links
- 229960000301 factor viii Drugs 0.000 title claims 2
- 108090000623 proteins and genes Proteins 0.000 claims abstract 13
- 102000004169 proteins and genes Human genes 0.000 claims abstract 13
- 238000000034 method Methods 0.000 claims abstract 7
- 210000004027 cell Anatomy 0.000 claims abstract 6
- 108010054218 Factor VIII Proteins 0.000 claims abstract 4
- 102000001690 Factor VIII Human genes 0.000 claims abstract 4
- 210000005260 human cell Anatomy 0.000 claims abstract 4
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 108091026890 Coding region Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 108010089996 B-domain-deleted factor VIII Proteins 0.000 abstract 1
- 230000006978 adaptation Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000009795 derivation Methods 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/028—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a herpesvirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
Abstract
Ta izum opisuje proizvodni postopek brez proteinov za proteine, ki imajo prokoagulatno aktivnost faktorja VIII. Splošno postopek vključuje derivacijo stabilnih humanih celičnih klonov z visoko produktivnostjo za faktor VIII z deletirano B-domeno in (2) prilagoditev celic na rast v mediju brez plazemsko izvedenih proteinov. Bolj natančno postopek vključuje transfekcijo humanih celic z vektorjem, kot je na sliki, ki obsega selektibilni marker in sekvenco, ki kodira protein, ki ima prokoagulantno aktivnost faktorja VIII, selekcioniranje celic s selekcijskim sredstvom in izoliranje klonov, ki izražajo visoke nivoje proteina, ki ima prokoagulantno aktivnost faktorja VIII.
Claims (8)
1 Patentni zahtevki 1. Postopek proizvodnje in izoliranja proteina, ki ima aktivnost faktoija VIII, ki obsega gojenje celic, imenovanih pri American Type Culture Collection kot CRL-12568, ki vključujejo sekvenco, ki kodira za protein, operabilno vezano na promotor, pri čemer gojenje poteka pod pogoji, ki so dovoljšnji, da se izrazi protein, in izoliranje proteina.
2. Postopek po zahtevku 1, označen s tem, da ima protein aminokislinsko sekvenco imenovano kot SEKV ID ŠT.: 1.
3. Postopek po zahtevku 2, označen s tem, da se protein izrazi na nivoju vsaj 2 pU/c/d, kadar celice gojimo v iz plazme izvirajočem mediju brez proteinov.
4. Postopek po zahtevku 3, kjer se protein izrazi na nivoju vsaj 4 pU/c/d.
5. Postopek po zahtevku 4, kjer se protein izrazi na nivoju vsaj 5 pU/c/d.
6. Humana celična linija, izvedena iz celic, imenovanih pri American Type Culture Collection kot CRL-12568, z vključitvijo sekvence, ki kodira za protein, ki ima aktivnost faktoija VIII, operabilno vezane na promotor.
7. Humana celična linija po zahtevku 6, ki izraža faktor VIII z deletirano B-domeno.
8. Celična linija, imenovana pri American Type Culture Collection kot CRL-12582.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/209,916 US6358703B1 (en) | 1998-12-10 | 1998-12-10 | Expression system for factor VIII |
| PCT/US1999/029169 WO2000034505A1 (en) | 1998-12-10 | 1999-12-08 | Expression system for factor viii |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SI20644A SI20644A (sl) | 2002-02-28 |
| SI20644B true SI20644B (sl) | 2009-04-30 |
Family
ID=22780858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI9920097A SI20644B (sl) | 1998-12-10 | 1999-12-08 | Ekspresijski sistem za faktor viii |
Country Status (26)
| Country | Link |
|---|---|
| US (10) | US6358703B1 (sl) |
| EP (1) | EP1137797B1 (sl) |
| JP (1) | JP4240818B2 (sl) |
| KR (1) | KR100616028B1 (sl) |
| AT (1) | ATE412765T1 (sl) |
| AU (1) | AU761801B2 (sl) |
| BG (1) | BG65431B1 (sl) |
| BR (1) | BRPI9916069B8 (sl) |
| CA (1) | CA2354845C (sl) |
| CZ (1) | CZ302330B6 (sl) |
| DE (1) | DE69939839D1 (sl) |
| DK (1) | DK1137797T3 (sl) |
| ES (1) | ES2315026T3 (sl) |
| HU (1) | HU228489B1 (sl) |
| IL (2) | IL143353A0 (sl) |
| NO (1) | NO329544B1 (sl) |
| NZ (1) | NZ512234A (sl) |
| PL (1) | PL200676B1 (sl) |
| PT (1) | PT1137797E (sl) |
| RO (1) | RO121604B1 (sl) |
| RU (1) | RU2249041C2 (sl) |
| SI (1) | SI20644B (sl) |
| SK (1) | SK286945B6 (sl) |
| TR (1) | TR200101592T2 (sl) |
| UA (1) | UA77383C2 (sl) |
| WO (1) | WO2000034505A1 (sl) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6475725B1 (en) | 1997-06-20 | 2002-11-05 | Baxter Aktiengesellschaft | Recombinant cell clones having increased stability and methods of making and using the same |
| US6180108B1 (en) * | 1998-12-10 | 2001-01-30 | Bayer Corporation | Vectors having terminal repeat sequence of Epstein-Barr virus |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US7572619B2 (en) * | 2000-03-22 | 2009-08-11 | Octagene Gmbh | Recombinant blood clotting factors |
| EP2110385A1 (en) | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
| WO2004075923A2 (en) * | 2003-02-26 | 2004-09-10 | Nektar Therapeutics Al, Corporation | Polymer-factor viii moiety conjugates |
| CA2526120A1 (en) * | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| US7485291B2 (en) * | 2003-06-03 | 2009-02-03 | Cell Genesys, Inc. | Compositions and methods for generating multiple polypeptides from a single vector using a virus derived peptide cleavage site, and uses thereof |
| WO2006050050A2 (en) * | 2004-10-29 | 2006-05-11 | Centocor, Inc. | Chemically defined media compositions |
| KR101468345B1 (ko) | 2004-11-12 | 2014-12-03 | 바이엘 헬스케어 엘엘씨 | Ｆｖｉｉｉ의 부위 지향 변형 |
| AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
| PL2253644T3 (pl) | 2005-12-20 | 2014-04-30 | Bristol Myers Squibb Co | Kompozycje i sposoby wytwarzania kompozycji |
| CA2709890A1 (en) | 2007-12-27 | 2009-07-09 | Andre Giovagnoli | Cell culture processes |
| KR101005967B1 (ko) * | 2008-04-12 | 2011-01-05 | (주)셀트리온 | 우수한 재조합 단백질을 생산하기 위한 인간 숙주 세포 |
| JP2011526151A (ja) * | 2008-06-25 | 2011-10-06 | バイエル・ヘルスケア・エルエルシー | 低下した免疫原性を有する因子ｖｉｉｉ変異タンパク質 |
| JP2012500250A (ja) | 2008-08-21 | 2012-01-05 | オクタファルマ アクチェン ゲゼルシャフト | 組換えにより産生したヒト第ｖｉｉｉ及び第ｉｘ因子 |
| CN107050437A (zh) * | 2008-09-03 | 2017-08-18 | 奥克塔法马股份有限公司 | 重组制备的因子viii的新型保护组合物 |
| CN108530543B (zh) | 2009-02-03 | 2023-06-23 | 阿穆尼克斯制药公司 | 延伸重组多肽和包含该延伸重组多肽的组合物 |
| CN102427823A (zh) * | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | 因子viii变体及使用方法 |
| CN102741275B (zh) | 2009-08-24 | 2016-08-03 | 阿穆尼克斯运营公司 | 凝血因子ix组合物及其制备和使用方法 |
| US20110150843A1 (en) * | 2009-10-30 | 2011-06-23 | National Institute Of Immunology | Method for the therapeutic correction of hemophilia a by transplanting bone marrow cells |
| US20130017997A1 (en) * | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| CA2835053C (en) | 2011-05-13 | 2020-07-07 | Octapharma Ag | A method of increasing the productivity of eucaryotic cells in the production of recombinant fviii |
| EP2804623B1 (en) | 2012-01-12 | 2019-08-07 | Bioverativ Therapeutics Inc. | Chimeric factor viii polypeptides and uses thereof |
| LT3564260T (lt) | 2012-02-15 | 2023-01-10 | Bioverativ Therapeutics Inc. | Viii faktoriaus kompozicijos ir jų gamybos bei panaudojimo būdai |
| EP2822577B1 (en) | 2012-02-15 | 2019-02-06 | Bioverativ Therapeutics Inc. | Recombinant factor viii proteins |
| WO2017180807A1 (en) | 2016-04-15 | 2017-10-19 | Baxalta Incorporated | Method and apparatus for providing a pharmacokinetic drug dosing regiment |
| TWI667255B (zh) | 2013-08-14 | 2019-08-01 | 美商生物化學醫療公司 | 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途 |
| SG11201605242YA (en) | 2014-01-10 | 2016-07-28 | Biogen Ma Inc | Factor viii chimeric proteins and uses thereof |
| IL257231B (en) | 2015-08-03 | 2022-09-01 | Bioverativ Therapeutics Inc | Factor ix fusion proteins and methods of making and using same |
| WO2018017923A1 (en) | 2016-07-22 | 2018-01-25 | Nektar Therapeutics | Conjugates of a factor viii moiety having an oxime-containing linkage |
| MX2019006444A (es) | 2016-12-02 | 2019-10-30 | Bioverativ Therapeutics Inc | Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos. |
| US10896749B2 (en) | 2017-01-27 | 2021-01-19 | Shire Human Genetic Therapies, Inc. | Drug monitoring tool |
| US20200245667A1 (en) * | 2017-09-13 | 2020-08-06 | Evolve Biosystems, Inc. | Oligosaccharide compositions and their use during transitional phases of the mammalian gut microbiome |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
| SI3793588T1 (sl) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc. | Postopki zdravljenja hemofilije A |
| EP3870206A4 (en) * | 2018-10-23 | 2023-04-26 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS OF MODULATION OF FACTOR VIII FUNCTION |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6045849B2 (ja) | 1980-08-25 | 1985-10-12 | 林原 健 | ヒトエリトロポエチンの製造方法 |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| KR890002004B1 (ko) * | 1984-01-11 | 1989-06-07 | 가부시끼 가이샤 도오시바 | 지폐류 판별장치 |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4970300A (en) * | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| AU5772886A (en) | 1985-04-12 | 1986-11-05 | Genetics Institute Inc. | Novel procoagulant proteins |
| US5198349A (en) | 1986-01-03 | 1993-03-30 | Genetics Institute, Inc. | Method for producing factor VIII:C and analogs |
| EP0254076B1 (en) * | 1986-07-11 | 1991-05-08 | Miles Inc. | Improved recombinant protein production |
| GB2197321B (en) | 1986-09-12 | 1990-10-03 | Genentech Inc | Method and vectors for obtaining continuous production of heterologous protein in a eukaryotic host cell line |
| IE69026B1 (en) * | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| ATE140027T1 (de) * | 1989-12-01 | 1996-07-15 | Pharming Bv | Herstellung rekombinanter polypeptide durch rinder und transgene methoden |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5661008A (en) | 1991-03-15 | 1997-08-26 | Kabi Pharmacia Ab | Recombinant human factor VIII derivatives |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| DK0874057T3 (da) * | 1993-06-10 | 2004-11-22 | Bayer Ag | Vektor og pattedyrcellelinie med forbedret produktionsevne |
| US5952198A (en) * | 1995-05-04 | 1999-09-14 | Bayer Corporation | Production of recombinant Factor VIII in the presence of liposome-like substances of mixed composition |
| DE19517194A1 (de) * | 1995-05-11 | 1996-11-14 | Giesecke & Devrient Gmbh | Vorrichtung und Verfahren zur Prüfung von Blattgut, wie z.B. Banknoten oder Wertpapiere |
| MX9504215A (es) | 1995-10-05 | 1997-04-30 | Inst Politecnico Nacional | Procedimiento mejorado para la purificacion de oligopeptidos con pesos moleculares de 1000 a 10,000 daltones, a partir de estractos leucocitos y su presentacion farmaceutica. |
| US5922959A (en) * | 1996-10-15 | 1999-07-13 | Currency Systems International | Methods of measuring currency limpness |
| US5923413A (en) * | 1996-11-15 | 1999-07-13 | Interbold | Universal bank note denominator and validator |
| US5804420A (en) * | 1997-04-18 | 1998-09-08 | Bayer Corporation | Preparation of recombinant Factor VIII in a protein free medium |
| CA2312291A1 (en) * | 1997-12-05 | 1999-06-17 | The Immune Response Corporation | Novel vectors and genes exhibiting increased expression |
| US6040584A (en) * | 1998-05-22 | 2000-03-21 | Mti Corporation | Method and for system for detecting damaged bills |
| US6528286B1 (en) | 1998-05-29 | 2003-03-04 | Genentech, Inc. | Mammalian cell culture process for producing glycoproteins |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US6180108B1 (en) | 1998-12-10 | 2001-01-30 | Bayer Corporation | Vectors having terminal repeat sequence of Epstein-Barr virus |
| US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
-
1998
- 1998-12-10 US US09/209,916 patent/US6358703B1/en not_active Expired - Lifetime
-
1999
- 1999-08-12 UA UA2001074777A patent/UA77383C2/uk unknown
- 1999-12-08 RO ROA200100649A patent/RO121604B1/ro unknown
- 1999-12-08 SI SI9920097A patent/SI20644B/sl active Search and Examination
- 1999-12-08 DE DE69939839T patent/DE69939839D1/de not_active Expired - Lifetime
- 1999-12-08 AU AU21701/00A patent/AU761801B2/en not_active Expired
- 1999-12-08 SK SK792-2001A patent/SK286945B6/sk not_active IP Right Cessation
- 1999-12-08 WO PCT/US1999/029169 patent/WO2000034505A1/en not_active Ceased
- 1999-12-08 PL PL349284A patent/PL200676B1/pl unknown
- 1999-12-08 JP JP2000586938A patent/JP4240818B2/ja not_active Expired - Lifetime
- 1999-12-08 DK DK99966068T patent/DK1137797T3/da active
- 1999-12-08 RU RU2001119156/13A patent/RU2249041C2/ru active
- 1999-12-08 TR TR2001/01592T patent/TR200101592T2/xx unknown
- 1999-12-08 BR BRPI9916069A patent/BRPI9916069B8/pt not_active IP Right Cessation
- 1999-12-08 CA CA002354845A patent/CA2354845C/en not_active Expired - Lifetime
- 1999-12-08 ES ES99966068T patent/ES2315026T3/es not_active Expired - Lifetime
- 1999-12-08 CZ CZ20012024A patent/CZ302330B6/cs not_active IP Right Cessation
- 1999-12-08 KR KR1020017007149A patent/KR100616028B1/ko not_active Expired - Lifetime
- 1999-12-08 IL IL14335399A patent/IL143353A0/xx unknown
- 1999-12-08 NZ NZ512234A patent/NZ512234A/xx not_active IP Right Cessation
- 1999-12-08 PT PT99966068T patent/PT1137797E/pt unknown
- 1999-12-08 EP EP99966068A patent/EP1137797B1/en not_active Expired - Lifetime
- 1999-12-08 AT AT99966068T patent/ATE412765T1/de active
- 1999-12-08 HU HU0200558A patent/HU228489B1/hu unknown
-
2001
- 2001-05-24 IL IL143353A patent/IL143353A/en not_active IP Right Cessation
- 2001-06-01 NO NO20012718A patent/NO329544B1/no not_active IP Right Cessation
- 2001-06-06 BG BG105567A patent/BG65431B1/bg unknown
- 2001-12-06 US US10/006,091 patent/US20020102730A1/en not_active Abandoned
-
2002
- 2002-01-15 US US10/047,257 patent/US20020115152A1/en not_active Abandoned
- 2002-08-22 US US10/225,900 patent/US7459525B2/en not_active Expired - Fee Related
-
2007
- 2007-04-25 US US11/789,580 patent/US20090036358A1/en not_active Abandoned
-
2010
- 2010-11-08 US US12/941,685 patent/US8207117B2/en not_active Expired - Fee Related
-
2012
- 2012-05-29 US US13/482,326 patent/US8945869B2/en not_active Expired - Fee Related
-
2013
- 2013-06-14 US US13/918,053 patent/US9249209B2/en not_active Expired - Fee Related
-
2015
- 2015-12-30 US US14/985,134 patent/US9650431B2/en not_active Expired - Fee Related
-
2017
- 2017-04-05 US US15/480,162 patent/US20170267745A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105567A (en) | Expression system for factor viii | |
| Rathjen et al. | Differentiation inhibiting activity is produced in matrix-associated and diffusible forms that are generated by alternate promoter usage | |
| Bendori et al. | Identification of two distinct functional domains on vinculin involved in its association with focal contacts. | |
| US20170183703A1 (en) | Method for Improved Isolation of Recombinantly Produced Proteins | |
| JP2003510070A (ja) | 細胞の無タンパク質かつ無血清の培養のための培地 | |
| CA2078721A1 (en) | Process for preparing human coagulation factor viii protein complex | |
| JPH02503744A (ja) | 第ＶＩＩＩ：ｃ因子型タンパク質の改良生産方法 | |
| JP2008109939A (ja) | 細胞膜に固定された抗凝固性融合タンパク質 | |
| JPH06504435A (ja) | 宿主細胞でのｐａｃｅの発現およびその使用法 | |
| Jenne et al. | Isolation and complete structure of the lymphocyte serine protease granzyme G, a novel member of the granzyme multigene family in murine cytolytic T lymphocytes. Evolutionary origin of lymphocyte proteases | |
| Mallory et al. | Expression and characterization of human apolipoprotein AI in Chinese hamster ovary cells. | |
| WO2000028065A1 (en) | Method for the production of fvii | |
| ES8504255A1 (es) | Procedimiento para la produccion de una hormona de crecimiento de porcino. | |
| ES2701763T3 (es) | Proteasa neutra producida de forma recombinante procedente de Paenibacillus polymyxa | |
| KR101054735B1 (ko) | 유전자 재조합 에카린 및 그를 제조하는 방법 | |
| JP2003506077A (ja) | 組換え安定細胞クローン、その産生およびその使用 | |
| CN104862318A (zh) | 利用转基因动物乳腺生物反应器生产单克隆抗体的方法 | |
| CA2690564A1 (en) | Transgenic mammals that produce exogenous proteins in milk | |
| KR100255228B1 (ko) | 글리코프로테인을 발현시키는 포유류 세포계 및 글리코프로테인의 제조 방법 | |
| AU600481B2 (en) | Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same | |
| CN103361342B (zh) | 一种转基因定位整合的方法及其应用 | |
| KR890701606A (ko) | 피치아 파스토리스로부터의 분비를 통한 동물 리소자임의 생산 및 이를 위한 조성물 | |
| Pavirani et al. | Recombinant proteins of therapeutic interest expressed by lymphoid cell lines derived from transgenic mice | |
| TW209247B (sl) | ||
| Shapiro et al. | A comparison of the membrane-bound and extracellular cyclic AMP phosphodiesterases of Dictyostelium discoideum |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| IF | Valid on the event date | ||
| OU02 | Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims |
Effective date: 20090306 |